TY - JOUR
T1 - Survey study of challenging experiences after ingesting psilocybin mushrooms
T2 - Acute and enduring positive and negative consequences
AU - Carbonaro, Theresa M.
AU - Bradstreet, Matthew P.
AU - Barrett, Frederick S.
AU - MacLean, Katherine A.
AU - Jesse, Robert
AU - Johnson, Matthew W.
AU - Griffiths, Roland R.
N1 - Funding Information:
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by NIH grants RO1DA03889 and 5T32 DA007209 and grants from the Council on Spiritual Practices and the Heffter Research Institute.
Publisher Copyright:
© 2016 The Author(s).
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Acute and enduring adverse effects of psilocybin have been reported anecdotally, but have not been well characterized. For this study, 1993 individuals (mean age 30 yrs; 78% male) completed an online survey about their single most psychologically difficult or challenging experience (worst "bad trip") after consuming psilocybin mushrooms. Thirty-nine percent rated it among the top five most challenging experiences of his/her lifetime. Eleven percent put self or others at risk of physical harm; factors increasing the likelihood of risk included estimated dose, duration and difficulty of the experience, and absence of physical comfort and social support. Of the respondents, 2.6% behaved in a physically aggressive or violent manner and 2.7% received medical help. Of those whose experience occurred >1 year before, 7.6% sought treatment for enduring psychological symptoms. Three cases appeared associated with onset of enduring psychotic symptoms and three cases with attempted suicide. Multiple regression analysis showed degree of difficulty was positively associated, and duration was negatively associated, with enduring increases in well-being. Difficulty of experience was positively associated with dose. Despite difficulties, 84% endorsed benefiting from the experience. The incidence of risky behavior or enduring psychological distress is extremely low when psilocybin is given in laboratory studies to screened, prepared, and supported participants.
AB - Acute and enduring adverse effects of psilocybin have been reported anecdotally, but have not been well characterized. For this study, 1993 individuals (mean age 30 yrs; 78% male) completed an online survey about their single most psychologically difficult or challenging experience (worst "bad trip") after consuming psilocybin mushrooms. Thirty-nine percent rated it among the top five most challenging experiences of his/her lifetime. Eleven percent put self or others at risk of physical harm; factors increasing the likelihood of risk included estimated dose, duration and difficulty of the experience, and absence of physical comfort and social support. Of the respondents, 2.6% behaved in a physically aggressive or violent manner and 2.7% received medical help. Of those whose experience occurred >1 year before, 7.6% sought treatment for enduring psychological symptoms. Three cases appeared associated with onset of enduring psychotic symptoms and three cases with attempted suicide. Multiple regression analysis showed degree of difficulty was positively associated, and duration was negatively associated, with enduring increases in well-being. Difficulty of experience was positively associated with dose. Despite difficulties, 84% endorsed benefiting from the experience. The incidence of risky behavior or enduring psychological distress is extremely low when psilocybin is given in laboratory studies to screened, prepared, and supported participants.
KW - Psilocybin
KW - adverse effects
KW - bad trip
KW - hallucinogen
KW - human
KW - psychedelic
KW - survey
UR - http://www.scopus.com/inward/record.url?scp=85002486041&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85002486041&partnerID=8YFLogxK
U2 - 10.1177/0269881116662634
DO - 10.1177/0269881116662634
M3 - Article
C2 - 27578767
AN - SCOPUS:85002486041
SN - 0269-8811
VL - 30
SP - 1268
EP - 1278
JO - Journal of Psychopharmacology
JF - Journal of Psychopharmacology
IS - 12
ER -